Please assess the completion status of the following clinical trial:

Trial Title: Korean Post-marketing Surveillance for Orencia®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Patients must be diagnosed with: Adult Rheumatoid arthritis (RA): adult patients with moderate-to-severe active RA~Or~* Juvenile idiopathic RA: juvenile patients aged 6 years and older with moderate-to-severe active RA~Exclusion Criteria:~* Children aged \<6 years~* Pregnant or lactating women~* Patients who are participating in another study~* Patients known to be hypersensitive to the active component of the surveillance drug or any other component of the surveillance drug~* Patients who had a positive tuberculosis screening test but were not treated with standard therapy before participating in the study~* Patients who have a positive hepatitis virus test~* Patients who were given a live vaccine concurrently with the surveillance drug or are expected to be given a live vaccine again within 3 months after discontinuation of the surveillance drug

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with active rheumatoid arthritis (Type: None): Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).